Back to Search Start Over

Microbiological Methods Used in the Enterics for Global Health Shigella Surveillance Study.

Authors :
Horne B
Badji H
Bhuiyan MTR
Romaina Cachique L
Cornick J
Hotwani A
Juma J
Ochieng JB
Abdou M
Apondi E
Atlas HE
Awuor AO
Baker KS
Ceesay BE
Charles M
Cunliffe NA
Feutz E
Galagan SR
Guindo I
Hossain MJ
Iqbal J
Jallow F
Keita NY
Khanam F
Kotloff KL
Maiden V
Manzanares Villanueva K
Mito O
Mosharraf MP
Nkeze J
Ikumapayi UN
Paredes Olortegui M
Pavlinac PB
Pinedo Vasquez T
Qadri F
Qamar FN
Qureshi S
Rahman N
Sangare A
Sen S
Peñataro Yori P
Yousafzai MT
Ahmed D
Jere KC
Kosek MN
Omore R
Permala-Booth J
Secka O
Tennant SM
Source :
Open forum infectious diseases [Open Forum Infect Dis] 2024 Mar 25; Vol. 11 (Suppl 1), pp. S25-S33. Date of Electronic Publication: 2024 Mar 25 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: Shigella is a major cause of diarrhea in young children worldwide. Multiple vaccines targeting Shigella are in development, and phase 3 clinical trials are imminent to determine efficacy against shigellosis.<br />Methods: The Enterics for Global Health (EFGH) Shigella surveillance study is designed to determine the incidence of medically attended shigellosis in 6- to 35-month-old children in 7 resource-limited settings. Here, we describe the microbiological methods used to isolate and identify Shigella . We developed a standardized laboratory protocol for isolation and identification of Shigella by culture. This protocol was implemented across all 7 sites, ensuring consistency and comparability of results. Secondary objectives of the study are to determine the antibiotic resistance profiles of Shigella , compare isolation of Shigella from rectal swabs versus whole stool, and compare isolation of Shigella following transport of rectal swabs in Cary-Blair versus a modified buffered glycerol saline transport medium.<br />Conclusions: Data generated from EFGH using culture methods described herein can potentially be used for microbiological endpoints in future phase 3 clinical trials to evaluate vaccines against shigellosis and for other clinical and public health studies focused on these organisms.<br />Competing Interests: Potential conflicts of interest. All authors: No potential conflicts of interest.<br /> (© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)

Details

Language :
English
ISSN :
2328-8957
Volume :
11
Issue :
Suppl 1
Database :
MEDLINE
Journal :
Open forum infectious diseases
Publication Type :
Academic Journal
Accession number :
38532949
Full Text :
https://doi.org/10.1093/ofid/ofad576